352018-90-7 Usage
General Description
Ethyl 1-(4-cyanophenyl)-4-piperidinecarboxylate is a chemical compound often used in scientific research. It is known for its role in the synthesis of pharmaceuticals, and as an intermediate in organic synthesis. Its IUPAC name is ethyl 4-(4-cyanophenyl)piperidine-1-carboxylate and it has a molecular formula of C16H18N2O3. As a cyanophenyl derivative, it's considered a member of phenylpiperidines -- a family of compounds typically possessing significant biological activities. While it is important in various fields, it is always essential to handle it carefully because it may pose certain health risks if not properly managed.
Check Digit Verification of cas no
The CAS Registry Mumber 352018-90-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,5,2,0,1 and 8 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 352018-90:
(8*3)+(7*5)+(6*2)+(5*0)+(4*1)+(3*8)+(2*9)+(1*0)=117
117 % 10 = 7
So 352018-90-7 is a valid CAS Registry Number.
InChI:InChI=1/C15H18N2O2/c1-2-19-15(18)13-7-9-17(10-8-13)14-5-3-12(11-16)4-6-14/h3-6,13H,2,7-10H2,1H3
352018-90-7Relevant articles and documents
Three new isostructural coordination polymers with Cd(II) clusters as the SBU: Synthesis, structural characterization, and luminescence properties
Lama, Prem,Bharadwaj, Parimal K.
, p. 5434 - 5440 (2011)
Three new isostructural coordination polymers, {Cd1.33L(Cl) 0.67(H2O)0.67}n (1), {Cd 1.33L(Br)0.67(H2O)0.67}n (2), and {Cd1.33L(I)sub
ANTI-INFECTIVE COMPOUNDS
-
Page/Page column 33, (2015/02/25)
The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.
USE OF SUBSTITUTED 2-PHENYLBENZIMIDAZOLES AS MEDICAMENTS
-
Page/Page column 36; 37, (2010/02/07)
The invention relates to the use of a substituted 2-phenylbenzimidazole of formula (I), where R1, R2, R3, R4, R5 and m have the meanings given in the claims, for the production of a medicament for the treatment or prevention of diseases in which glucagon receptors are implicated and novel compounds of formula (I), where R1 is a group of formula (II).
Xn:Harmful;
